PDCD1 and small cell lung carcinoma: The targeted gene expression analysis of the above DEGs in 14 tumors of patients with SCLC who received anti–PD-1 treatment improved that four patients with “immune hot” features tended to benefit more from ICI than the other patients (n = 10) with “immune cold” SCLC (56).